Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Paula Swain Biography and Net Worth

EVP of Incyte

Paula Swain joined Incyte in January 2002 and serves as Executive Vice President of Human Resources. Before joining the company, Ms. Swain spent nearly 10 years with DuPont (acquired by Bristol-Myers Squibb Company in 2001), where she served as Vice President and Senior Vice President of Human Resources. She has also held human resource planning and employee relations positions with Chase Manhattan Bank, Marine Midland Bank, and Delaware Trust Company. Ms. Swain received her BA in psychology from Rockhurst College and graduated from the strategic human resources planning program at Harvard Business School.

What is Paula J. Swain's net worth?: The estimated net worth of Paula J. Swain is at least $3.48 million as of March 31st, 2020. Ms. Swain owns 50,132 shares of Incyte stock worth more than $3,479,161 as of December 17th. This net worth estimate does not reflect any other investments that Ms. Swain may own. Learn More about Paula J. Swain's net worth.
How do I contact Paula J. Swain?: The corporate mailing address for Ms. Swain and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Paula J. Swain's contact information.
Has Paula J. Swain been buying or selling shares of Incyte?: Paula J. Swain has not been actively trading shares of Incyte during the past quarter. Most recently, Paula J. Swain sold 10,870 shares of the business's stock in a transaction on Friday, January 7th. The shares were sold at an average price of $73.31, for a transaction totalling $796,879.70. Learn More on Paula J. Swain's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (CEO & Chairman), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 65,984 shares worth more than $4,322,270.69. The most recent insider tranaction occured on December, 16th when insider Thomas Tray sold 650 shares worth more than $45,051.50. Insiders at Incyte own 17.6% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 12/16/2024.

Paula J. Swain Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/7/2022	Sell	10,870	$73.31	$796,879.70
3/31/2020	Sell	2,329	$71.44	$166,383.76	50,132
2/19/2020	Sell	2,500	$80.00	$200,000.00	50,993
1/15/2020	Sell	2,500	$81.12	$202,800.00	44,112
12/16/2019	Sell	2,500	$91.61	$229,025.00	44,112
11/15/2019	Sell	2,500	$86.46	$216,150.00	44,112
10/22/2019	Sell	2,500	$80.00	$200,000.00	44,112
9/18/2019	Sell	2,500	$80.00	$200,000.00	44,112
8/15/2019	Sell	2,500	$80.96	$202,400.00	44,112
7/15/2019	Sell	2,500	$80.00	$200,000.00	44,751
6/17/2019	Sell	2,500	$80.00	$200,000.00	39,013
4/1/2019	Sell	10,000	$87.01	$870,100.00	38,295
3/1/2019	Sell	10,000	$86.68	$866,800.00
2/1/2019	Sell	10,000	$81.19	$811,900.00	41,124
1/4/2019	Sell	30,000	$70.00	$2,100,000.00	62,324
9/4/2018	Sell	10,000	$73.21	$732,100.00
8/21/2018	Sell	10,000	$70.00	$700,000.00	42,324
4/30/2018	Sell	80,000	$62.43	$4,994,400.00	39,467
8/31/2017	Sell	20,000	$140.00	$2,800,000.00	55,067
10/20/2016	Sell	10,000	$90.00	$900,000.00	39,248
9/23/2016	Sell	20,000	$90.00	$1,800,000.00	49,248
7/29/2016	Sell	60,000	$90.00	$5,400,000.00	89,248
1/15/2016	Sell	13,531	$76.96	$1,041,345.76	23,693
2/17/2015	Sell	17,500	$76.90	$1,345,750.00
1/20/2015	Sell	17,500	$74.17	$1,297,975.00
1/5/2015	Sell	17,500	$73.90	$1,293,250.00
9/5/2013	Sell	94,444	$35.06	$3,311,206.64

Paula J. Swain Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $69.40

$68.51

$69.74

50 Day Range

MA: $72.29

$65.07

$83.38

2 Week Range

Now: $69.40

$50.35

$83.95

Volume

1,971,461 shs

Average Volume

2,337,362 shs

Market Capitalization

$13.37 billion

P/E Ratio

495.71

Dividend Yield

N/A

Beta

0.69